• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Basit Chaudhry: Feedback Provides Potential Changes for the OCM

Video

Basit Chaudhry, MD, PhD, founder of Tuple Health, discussed the feedback he's heard from practices about the Oncology Care Model and how these opinions could be used to guide potential changes.

Basit Chaudhry, MD, PhD, founder of Tuple Health, discussed the feedback he's heard from practices about the Oncology Care Model and how these opinions could be used to guide potential changes.

Transcript (slightly modified)

Based on feedback from participating practices, are there changes you think should be made to the Oncology Care Model?

Yes, I think one of the areas where we’ve gotten a lot of feedback on is data reporting requirements on both the quality measures and the clinical measures. I think it’s a fundamentally important idea in measuring quality and also the clinical data, this makes sense, but I think the burden has been significant for practices.

Medicare’s tried to improve that, particularly changing the timelines for reporting requirements, but I think moving that forward would be important, particularly prioritizing which kind of data is really going to be the key to moving value-based payment forward in oncology. I think it would reduce the kind of challenges that participants are facing.

A second area would be to continue to evolve and improve the risk adjustment model and the prediction model in OCM, to make sure that’s clinically informed as possible and really reflects the complexity of the different patients that practices take care of, I think is very important.

I think a third thing we’ve heard about quite often is just complexities that are arising around model overlap between OCM and other payment models that Medicare is putting into place, particularly around MACRA and MIPS.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.